公开(公告)号：US12161760B2

公开(公告)日：2024-12-10

申请号：US17045127

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Matthias Alexander Oberli ,  Owen O'Connor ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: A61K9/50 ,  A61K35/28 ,  A61K35/30 ,  C07K14/62 ,  C07K14/755 ,  C12N9/64

Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20240400645A1

公开(公告)日：2024-12-05

申请号：US18656168

申请日：2024-05-06

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Ekta SETH CHHABRA ,  Alison INNES ,  Dan RUDIN ,  Kara RICE ,  Nancy WONG ,  Suresh KATRAGADDA

IPC: C07K14/755 ,  A61K38/00 ,  A61P7/04

Abstract: The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D′ domain of VWF and a D3 domain of VWF at a dosing interval.

公开(公告)号：US12134632B2

公开(公告)日：2024-11-05

申请号：US18153669

申请日：2023-01-12

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Glen Bolton ,  Keith Selvitelli

IPC: A61L2/00 ,  A61K35/14 ,  A61K35/16 ,  A61K38/00 ,  C07K1/16 ,  C07K1/22 ,  C07K14/755 ,  C07K16/06

Abstract: The present invention is directed to a method of inactivating virus that is present during production of a polypeptide of interest. In particular, the present invention is directed to a method of on-column virus inactivation using a low pH and high salt wash solution that effectively inactivates viruses with minimum recovery loss of the polypeptide.

公开(公告)号：US20240350672A1

公开(公告)日：2024-10-24

申请号：US18617239

申请日：2024-03-26

Applicant: BIOVERATIV THERAPEUTICS INC.

Inventor： Tongyao LIU ,  Ekta Seth CHHABRA ,  Siyuan TAN

IPC: A61K48/00 ,  A61K38/00 ,  A61P7/04 ,  C07K14/755 ,  C12N15/85

CPC classification number: A61K48/0058 ,  A61P7/04 ,  C07K14/755 ,  C12N15/85 ,  A61K38/00

Abstract: The present disclosure provides codon optimized Factor VIII sequences, vectors, and host cells comprising codon optimized Factor VIII sequences, polypeptides encoded by codon optimized Factor VIII sequences, and methods of producing such polypeptides.

公开(公告)号：US20240335564A1

公开(公告)日：2024-10-10

申请号：US18706642

申请日：2022-11-01

Applicant: GRITGEN THERAPEUTICS LIMITED

Inventor： Tenghui YU ,  Zhou YANG ,  Jianghong ZHANG ,  Lijun SHEN ,  Yi RAO

IPC: A61K48/00 ,  A61K38/00 ,  A61P7/04 ,  C07K14/755 ,  C12N15/86

CPC classification number: A61K48/0058 ,  A61P7/04 ,  C07K14/755 ,  C12N15/86 ,  A61K38/00 ,  C12N2750/14143 ,  C12N2830/50

Abstract: An isolated nucleic acid molecule and the use thereof. The nucleic acid molecule comprises a liver-specific expression regulatory element and a target gene, and the liver-specific expression regulatory element can increase the expression amount and/or activity of the target gene. Further provided are a vector a diagnostic or pharmaceutical composition containing the isolated nucleic acid molecule, and the use thereof.

公开(公告)号：US12071468B2

公开(公告)日：2024-08-27

申请号：US17688588

申请日：2022-03-07

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Meinhard Hasslacher ,  Martin Feichtinger ,  Philipp M. Bärnthaler ,  Christa Mayer ,  Birgit Reipert ,  Mantas Malisauskas ,  Julia Anzengruber

IPC: C07K14/755 ,  A61K38/00 ,  B01D15/32 ,  B01D15/34 ,  B01D15/36 ,  C07K1/16 ,  C07K1/18 ,  C07K1/36

CPC classification number: C07K14/755 ,  B01D15/327 ,  B01D15/34 ,  B01D15/363 ,  C07K1/16 ,  C07K1/18 ,  C07K1/36 ,  A61K38/00 ,  B01D15/363 ,  B01D15/34 ,  B01D15/363 ,  B01D15/327 ,  B01D15/34

Abstract: The present invention relates to a method for purifying a Factor VIII (FVIII) subspecies from a composition comprising FVIII, said method comprising an anion exchange chromatography step, a size exclusion chromatography step, and a concentration step. The invention also relates to a composition comprising a purified FVIII subspecies.

公开(公告)号：US20240254197A1

公开(公告)日：2024-08-01

申请号：US17774450

申请日：2022-02-11

Applicant: Sichuan Real&Best Biotech Co., Ltd.

Inventor： Biao Dong ,  Bo Zhang ,  Jingya Ye ,  Lin Xiao ,  Zhaoyue Zheng ,  Li Yang ,  Yu Liu

IPC: C07K14/755 ,  A61K38/00 ,  C12N15/86

CPC classification number: C07K14/755 ,  C12N15/86 ,  A61K38/00 ,  C12N2750/14143

Abstract: The present invention relates to an engineered human factor VIII polypeptide, which includes at least two substituted amino acids in A1 domain of hFVIII. In some embodiments, the substituted amino acids comprise L50V and L152P. In some embodiments, the substituted amino acids further comprise one or more of amino acid substitutions selected from the group consisting of D20S, G22L, I61T, D115E, F129I, G132D, Q139E, and L159F. The present invention also relates to engineered hFVIII polypeptide encoding nucleic acid fragment, an expression vector or a rAAV vector contains such nucleic acid fragment, and a method of using engineered hFVIII polypeptide to treat hemophilia A patients.

公开(公告)号：US20240166722A1

公开(公告)日：2024-05-23

申请号：US18468535

申请日：2023-09-15

Applicant: AAVnerGene Inc.

Inventor： Qizhao WANG ,  Daozhan YU

IPC: C07K14/755 ,  C12N15/86

CPC classification number: C07K14/755 ,  C12N15/86 ,  A61K38/00

Abstract: Modified human factor VIII polypeptides with enhanced factor VIII activity are described. In some embodiments, the modified human factor VIII polypeptides comprise one or more amino acid substitutions at positions A20, T21, F57, L69, I80, L178, R199, H212, I215, R269, 1310, L318, S332, R378, I610 and/or I661. Such polypeptides and viral vectors encoding such polypeptides may be used for treatment of FVIII deficiencies, such as hemophilia A.

公开(公告)号：US20240052012A1

公开(公告)日：2024-02-15

申请号：US18356688

申请日：2023-07-21

Applicant: CSTS Health Care Inc.

Inventor： Giannoula Lakka KLEMENT ,  Qian LIU

IPC: C07K14/705 ,  C07K14/755 ,  A61K47/69 ,  A61P35/00

CPC classification number: C07K14/70564 ,  C07K14/755 ,  A61K47/6901 ,  A61P35/00

Abstract: The present disclosure provides compositions and methods comprising platelets loaded with at least two agents, with each agent being loaded into a distinct α-granule type of the platelet. Agents loaded into platelets are generally protected from degradation and the subject is protected from toxicity, if any, from the agent. These benefits, coupled with the platelets' natural ability to home to sites of injury, inflammation, and/or angiogenesis, helps ensure that a therapeutically effective amounts of the agents are delivered to a target site.

公开(公告)号：US20240043500A1

公开(公告)日：2024-02-08

申请号：US18483108

申请日：2023-10-09

Applicant: COLZYX AB

Inventor： Matthias MÖRGELIN ,  Suado ABDILLAHI

IPC: C07K14/78 ,  A61L27/54 ,  A61L15/44 ,  C07K14/47 ,  A61P17/02 ,  A61P31/04 ,  A01N47/44 ,  A61L15/32 ,  A61L17/00 ,  A61L17/14 ,  A61L24/00 ,  A61L24/10 ,  A61L27/22 ,  A61L27/24 ,  A61L27/34 ,  A61L27/60 ,  A61L29/04 ,  A61L29/08 ,  A61L29/16 ,  A61L31/04 ,  A61L31/10 ,  A61L31/16 ,  C07K14/755

CPC classification number: C07K14/78 ,  A61L27/54 ,  A61L15/44 ,  C07K14/4723 ,  A61P17/02 ,  A61P31/04 ,  A01N47/44 ,  A61L15/32 ,  A61L15/325 ,  A61L17/005 ,  A61L17/145 ,  A61L24/0015 ,  A61L24/102 ,  A61L24/108 ,  A61L27/227 ,  A61L27/24 ,  A61L27/34 ,  A61L27/60 ,  A61L29/045 ,  A61L29/048 ,  A61L29/085 ,  A61L29/16 ,  A61L31/044 ,  A61L31/047 ,  A61L31/10 ,  A61L31/16 ,  C07K14/755 ,  A61L2300/404 ,  A61K9/7023

Abstract: The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition.